AstraZeneca to buy Alexion for US$39b to expand in immunology

FRANKFURT (Dec 12): Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business…